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INTRODUCTION 
Historically schizophrenia was conceptualized as a disorder with 
poor prognosis and outcome. The older term “Dementia Praecox” itself 
carried negative connotation that this disorder would be a chronic, 
progressive and debilitating disorder. Over the years, extensive research 
on course and outcome of schizophrenia in Western population found a 
variable outcome 
In the year 2002, The Science journal published that once the 
symptoms of schizophrenia occur, they remain for life and they produce 
maximum disability (1). Obviously there is evidence that a certain 
percentage of schizophrenia patients have poor outcome. It is logical to 
apply criteria of deficit syndrome to this population. The remaining 
population has either good or in between good and poor outcome. This 
remitted group needs clinical criteria which could be achieved by treating 
clinician or at least can work towards them (1)
In the year 2005, the Remission in Schizophrenia Working Group 
(RSWG) put forth definition for symptomatic remission and set specific 
operational criteria for its assessment. They also said that the validity of 
this criterion in relation to outcome measures of schizophrenia need to be 
studied in future
. 
 
 (2). 
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Since the publication of the remission criteria in March 2005, more 
than 50 articles on this topic have been published. Reviewing these 
articles brings about various problems (3)
• Many of the studies have used the symptom-severity remission 
criteria omitting the time criterion. 
: 
• Some studies have used other outcome measures than the proposed 
PANSS, SANS/SAPS, or BPRS scales (e.g., CGI-S).  
• Some studies using the BPRS have not assessed the two missing 
negative symptoms of the severity criteria. 
• There is a huge variation with respect to duration of study period. 
• Some studies suffered from high dropout rates, if reported at all. 
• Finally, there is a huge variation regarding sample selection (e.g., 
acute inpatients vs. stable outpatients, first episode vs. multiple 
episode patients, schizophrenia vs. schizophrenia spectrum 
disorders, first-episode schizophrenia vs. first-episode psychosis 
including affective psychosis, patients with co morbid substance 
use disorder in or excluded, major differences in symptom severity 
at baseline, etc)(3)
However most of studies done in western population found the criteria for 
symptomatic remission can be attained and sustained. Better symptomatic 
. 
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status is also found to correlate with better functional outcome, better 
quality of life and cognitive functioning (3). 
Compared to western population, it was found that non-white non-
Europeans have more benign course and more favorable outcome. Studies 
from Hong Kong, India and Srilanka showed favorable results. WHO 
sponsored studies also showed better outcome in developing countries. 
But studies comparing symptomatic remission with functional outcome in 
Indian population is lacking.  
Remitted patients still showed areas with an inadequate level of 
functioning. Functional deficits were most often seen in social relations 
(40%), work (29%) and daily life activities (17%). Best functioning was 
assessed for self-care, self-control, health management and medical 
treatment. A moderate to severe level of disorganization and emotional 
distress was observed in 38% and impaired subjective well-being in 29% 
of patients defined as being in symptomatic remission(4). 
With this Background, this study tries to assess functional outcome 
in symptomatic remitted schizophrenia patients compared to unremitted 
patients in Indian population. 
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REVIEW OF LITERATURE 
Schizophrenia is arguably the most puzzling of psychiatric 
syndromes and one of its most debilitating. It is characterized by 
disordered cognition, including a “gain of –function” in psychotic 
symptoms and a “loss of –function” in specific cognitive functions, such 
as working and declarative memory, but without the progressive dementia 
that characterizes classical neurodegenerative disorders. Although its 
phenomenology is fascinating, its pathophysiology and etiology remain 
unclear, and people with the illness suffer greatly. 
The epidemiology of schizophrenia around the world has been 
examined and defined, along with its distinctive disease characteristics 
such as the unusual age of onset and its lifelong symptom course. Clinical 
genetics, postmortem tissue neurochemistry, and brain imaging 
characteristics (structural, functional, and molecular) have advanced, if 
not yet defined, the illness pathophysiology. Cognition in schizophrenia 
has been reconceptualized as a feature that is critically important to 
outcome and to a full disease understanding. 
Current treatments have come further than early scientists would 
have thought: Pharmacology, based on initial serendipitous observations, 
has been taken to a sophisticated level of application, while psychosocial 
approaches are demonstrating clear efficacy. The involvement of 
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individuals with the illness in the process of recovery has been gratifying 
to observe. 
Although there are pharmacological agents to treat psychosis and 
cognitive remediation strategies to improve psychosocial function, 
physicians cannot claim to have the armamentarium of treatments to fully 
restore health to individuals with schizophrenia. Antipsychotic drugs, 
including the first and second generations, allowed some peace from 
florid psychosis, but not a full return of brain health, resilience, or mental 
function. Individuals with the illness still fight huge ongoing battles for 
sanity every day. 
Schizophrenia is perhaps the most dramatic and tragic 
manifestation of mental illness known to mankind. The consequences of 
the illness for the individual affected, his or her family, and society in 
general are devastating. A pessimistic view about outcome of 
schizophrenia is very common among treating clinicians. Sometimes 
schizophrenia is considered as an illness with permanent deficit brain 
disorder. 
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Outcome of schizophrenia 
There is a general opinion that schizophrenia is uniformly a 
disorder with deteriorating course. This is based purely on biased clinical 
observation. The idea originated directly from the work of Kraepelin. In 
19th century, he followed the course of psychoses patients admitted in a 
custodial institution in Germany. He observed this group to have poor 
course. He grouped this into single disease entity called dementia 
praecox(5)
Last century has attempted to study the outcome of schizophrenia 
but results have to be read with caution because data on longitudinal 
.  
Unfortunately the institution provided residential care for people 
with the most severe, complex, and debilitating illness. Hence 
Kraepelin`s conclusion is based on a sample biased towards worst 
outcome. His observation did not include the complete range of course or 
outcome of schizophrenia. 
Currently the institutional settings are disappearing with more 
people being treated on outpatient basis. However clinical case load 
consists mostly of patients with poor prognosis who require frequent 
contact with psychiatric service, rather than the population sample of all 
persons diagnosed with schizophrenia and thus prolonging the illusion 
that schizophrenia is invariably chronic and deteriorating.  
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course remain weak. Moreover studying the longitudinal course and 
outcome of schizophrenia is difficult because of methodological issues 
and the difficulties associated with follow up study. Methodological 
heterogeneity in the past studies are (5)
1. Sample consisted of admitted patients; 20% patients never get 
admitted. 
: 
2. Different diagnostics used at various period, questions the validity 
of diagnosis 
3. Duration of illness is different at entry of the study 
4. Follow up period is variable 
5. High attrition rate; more than 20% 
6. Different methods used to assess course and outcome.  
7. Heterogeneity of the general population.  
8. Statistical weakness and confounding biases 
9. Differences in management of schizophrenia 
The information on natural course of schizophrenia is very limited. 
Throughout history, psychotic illness was treated at custodial care or 
religious or cultural way. Since 1950s, most of the schizophrenia patients 
were treated with neuroleptics. Recent studies which describe the natural 
course of illness are rare. 
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A recent study from India was able to examine outcomes in 
individuals who had never received treatment for schizophrenia (a closer 
approximation to natural history, notwithstanding the potential influence 
of cultural context). The course for the untreated group was 
heterogeneous and rather similar to the course of those who had received 
treatment (5)
 
.        
Outcome is a multidimensional construct that at the minimum 
requires description of domains for (1) clinical (symptoms and treatment) 
and (2) social (e.g., independent living, maintenance of social 
relationships, and employment). Such domains are likely, in part, to 
overlap. However, studies examining risk factors for the persistence of 
schizophrenia should attempt to measure symptom course and social 
domains independently, as the different domains probably do not co vary 
directly, and could be  more likely be the result of different influences, at 
least in part.  
Outcome of schizophrenia, as measured by various studies, were in 
part dependent on outcome definition designated for the particular study. 
Thus some have found better outcome with liberal outcome definition 
while some have found poor outcome with stringent criteria. Following 
table lists the studies differing on this issue. 
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Study 
Event 
Rate 
Definition of Poor Symptom Outcome 
Muller, 1951 (Germany) 0.41 Insidious chronic course, continual need for full time care 
Bland, 1978 (Alberta) 0.16 Severe chronic social and/or intellectual deficit 
Stephens,1978 (Baltimore) 0.3 
Unimproved, evidence of chronic sustained chronic 
psychotic symptoms 
Ciompi, 1980 
(Switzerland) 
0.18 Severe chronic phase 
Salokangas, 1983 (Finland) 0.24 Continuous psychotic symptoms 
Rabiner, 1986 (New YorK0 0.44 Relapsed or in-episode evidence of psychotic symptoms 
Sartorius, 1986 
(Multinational) 
0.4 Unremitting psychotic symptoms 
Shepherd,1989 (United 
Kingdom) 
0.43 Remained impaired throughout follow-up 
McCreadie,1989 (Scotland) 0.39 Psychotic symptoms present at two year follow up 
Mameros,1992 (Germany) 0.17 Psychotic symptoms present at time of follow up 
Thara,1994 (India) 0.07 Continuous psychotic symptoms 
an der Heiden,1995 
(Germany) 
0.59 Moderate to severe symptoms at time of follow up 
Mason,1996 (United 
Kingdom) 
0.34 
Continuous psychotic symptoms in the 2 years prior to 
follow up 
Wieselgren,1996 (Sweden) 0.14 
"Poor outcome" evidence of ongoing persistent psychotic 
symptoms 
Ganev,1998 (Bulgaria) 0.45 
Chronic continuous psychotic symptoms in the 2 years prior 
to assessment 
Wiersma,1998 
(Netherlands) 
0.11 
Chronic continuous psychotic symptoms over full follow-up 
time  
Vazquez - Barquero,1999 
(Spain) 
0.09 Chronic continuous psychotic symptoms 
Stirling,2003 (United 
Kingdom) 
0.06 GAF=1 at follow up 
 
Poor outcome event rate ranges from 0.06 to 0.44 depending on definition 
of poor outcome (5)
 
. 
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Study Event Rate Definition of Good Symptom Outcome 
Muller, 1951 (Germany) 0.33 Recovered or substantially improved at the time of discharge 
Bland, 1978 (Alberta) 0.21 Symptomatic recovery with no social or intellectual deficit throughout follow-up 
Stephens,1978 
(Baltimore) 0.24 
Recovered "included patients with symptoms but no social 
impairment" 
Ciompi, 1980 
(Switzerland) 0.27 Remitted completely or having only residual symptoms 
Salokangas, 1983 
(Finland) 0.55 Complete recovery or occasional mild psychotic symptoms 
Rabiner, 1986 (New 
YorK0 0.56 
Symptomatic remission for at least three months prior to 
assessment 
Sartorius, 1986 
(Multinational) 0.39 1 Episode with no or minimal symptoms at follow-up 
Shepherd,1989 (United 
Kingdom) 0.22 Had no relapse during follow-up period 
McCreadie,1989 
(Scotland) 0.37 
Asymptomatic and functioning adequately at the time of 
follow up 
Mameros,1992 
(Germany) 0.07 Full remission after first episode 
Thara,1994 (India) 0.17 Complete recovery without relapse during the follow up period 
an der Heiden,1995 
(Germany) 0.25 Full recovery over follow up period 
Mason,1996 (United 
Kingdom) 0.52 Full remission in the 2 years prior to outcome assessment 
Wieselgren,1996 
(Sweden) 0.3 Dichotomized variable "Good outcome" vs. "Poor outcome" 
Ganev,1998 (Bulgaria) 0.38 Complete remission in 2 years prior to follow up assessment 
Wiersma,1998 
(Netherlands) 0.27 Complete remission , never readmitted 
Vazquez - Barquero,1999 
(Spain) 0.32 Symptomatic recovery, may have residual symptoms 
Stirling,2003 (United 
Kingdom) 0.47 Categorical measure GAF=4 at time of follow up 
 
Good outcome rate ranges from 0.07 to 0.56 depending on good outcome 
definition (5)
 
. 
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      There is a small body of literature comparing the patterns and 
frequencies of outcome using different perspectives, but few studies have 
examined multiple perspectives in the same sample. One such study, 
carried out in South Verona's community care service, found a distinction 
between objective and subjectively rated outcome. Patients were 
especially troubled by persistent unmet social and functional needs. This 
may have important implications for the clinical management of people 
with schizophrenia, particularly since psychiatric services currently 
emphasize the pharmacological and psychological treatments, while de-
emphasizing social and functional interventions, yet unmet social needs 
seems to influence disability over the longitudinal course. 
 
Meta analysis of prospective studies done from 1996 to 2003 
measuring the outcome of first episode schizophrenia found good 
outcomes in 42 percent, intermediate outcomes in 35 percent, and poor 
outcomes in 27 percent. The results are similar to earlier meta-analysis of 
long-term follow-up studies (published between the turn of the 20th 
century until 1998 with follow-up period greater than 1 year). The 
absence of a uniform definition for outcome across studies makes direct 
comparison difficult (5)
 
. 
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Considering the previous researches, studies conclude the following 
findings. 
 
• The course of schizophrenia is highly variable. Possible course 
patterns ranges from complete recovery to continuous unremitting. 
Between such extremes, a group of patients present with multiple 
episodes of psychosis interspersed with partial remission (5)
• Nearly 40% of the patients diagnosed to have schizophrenia have great 
improvement after an average of 6 years. While this is a significant 
change compared to previous pessimistic view based on Kraepelin’s 
concept, the very fact that schizophrenia is associated with permanent 
disability affecting quality of life, personal and social performance 
cannot be neglected
. 
 (5)
• The illness usually stabilizes in about 5 years. Thus course of illness 
varies among patients within this period after which it plateaus 
. 
(5)
• There is no reliable set of predictors for course and outcome. The 
identified predictors amount to only 30% of variance in predicting 
outcome 
.  
(5)
The World Health Organization (WHO) International Study of 
Schizophrenia found that the most reliable predictor of negative long-
term outcome is unremitting psychosis in the first 2 years following its 
onset. This finding and others are driving the research along these lines 
. 
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that is starting to show that early assertive intervention leading to 
decreases in psychotic symptoms is a promising direction for improved 
long-term outcomes. Hence achieving symptomatic remission is one step 
towards good outcome. 
 
Remission and Recovery in Schizophrenia 
For decades, the major hindrance for comparison of studies 
measuring outcome is non availability of uniform definition of remission 
in schizophrenia.  
 
What is ‘Response’? 
Response can be defined as “a clinically meaningful improvement 
in a patient`s psychopathology, irrespective of whether he ⁄ she is still 
symptomatic at the end or not” (6). Improvement in psychopathology is 
usually measured by CGI scale or more specific scales like PANSS, 
BPRS etc. 
Response definition based on the CGI scale  
The Clinical Global Impression severity (CGI-S) measures severity 
of illness. Clinician rates the severity of illness based on patient’s 
behavior in last week. Scores can be from 1-7. 
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Clinical global impression scale improvement (CGI-I) is an 
intuitive measure of clinical improvement (7)
• Clinicians have at least an intuitive idea as to who a much improved or 
only mildly ill patient is.  
. The CGI-I score assesses the 
patient`s improvement or worsening since the start of the study. Scores 
can be from 1-7. 1 = very much improved 2 = much improved 3 = 
minimally improved 4 = no change 5 = minimally worse 6 = much worse 
7 = very much worse 
Advantage of CGI 
• CGI is not very time consuming, because there are only two crosses to 
make. 
Disadvantages of CGI scale: 
• Psychometric properties of the CGI scale were never well 
examined(8)(9)(10)(11)(12)
• The CGI scale is insensitive for differences between two 
interventions
. 
(13)(14)
• Doesn`t mention about psychopathology 
. 
 
So to avoid these disadvantages, new versions of the CGI scale that 
are specific for bipolar disorder (15) and schizophrenia (14) have recently 
been developed.  
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The schizophrenia version uses the same items and scores. It also 
provides anchor points for severity, subscales for psychopathology and 
cognitive functioning with same scoring system. The psychometric 
property of new version is also validated (14). 
 
Response definitions based on rating scales such as the BPRS or the 
PANSS 
Brief Psychiatric Rating Scale (BPRS) or Positive and Negative 
Syndrome Scale (PANSS) are well validated scales for assessing 
psychopathology. They also have anchor points for scoring. Response is 
measured by percentage of improvement from baseline score.  
Disadvantage of PANSS or BPRS in measuring response 
Time Consuming and percentage Change from baseline score is not 
informative about actual severity. 
 
What is ‘Remission’? 
In general, remission is defined as a state in which there are no 
clinically significant symptoms.  At a glance this definition seems 
unattainable in schizophrenia. However many studies have found that 
schizophrenia patients achieve complete remission after treatment even it 
is first episode (16)(17) or multiple episode (18)(19)(20)(21)(22). 
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The symptom complex of schizophrenia is varied and also related 
to phase of illness. Hence a scale PANSS or BPRS alone cannot define 
remission at all stage of illness. So in the year 2005, Andreasen et al (2) 
and van Os et al (1) proposed remission criteria and operationalized it. 
According to these criteria, a patient is in symptomatic remission if eight 
specific items of the PANSS are rated mild or better i.e. score 3 or less. It 
is assumed that score of 3 or less will not interfere with functioning. The 
remission is sustained if this is maintained for at least 6 months. 
Remission criteria proposed by Andreasen utilizes the symptoms that are 
specifically used for diagnosis of schizophrenia based on ICD-10 or  
DSM IV TR.  
 
Symptomatic Remission and outcome studies 
In 2005, the Remission in Schizophrenia Working Group (RSWG) 
(2) announced the definition of remission in schizophrenia. They also set 
criteria for its assessment .Remission is defined as a state where the levels 
of core schizophrenic symptoms are very low such that they don’t 
interfere with individual`s behavior and is insufficient to make a 
diagnosis of schizophrenia based on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV). 
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 The criteria consist of two elements: 
1) A symptom-based criterion: 
The seven diagnostically relevant items from the DSM-IV were then 
cross-matched to three different rating scales 
a) Positive and Negative Syndrome Scale [PANSS] 
b) Scale for the assessment of negative symptoms and positive symptoms 
[SANS/SAPS] 
c) Brief Psychiatric Rating Scale [BPRS] 
They correspond to eight items in the PANSS and these item score should 
be ≤3 to classify them as remitted. 
 The eight symptoms include:  
(i) Delusions (ii) Unusual thought content (iii) Hallucinatory behavior 
(iv) Conceptual disorganization (v) Mannerisms/posturing  
(vi) Blunted affect (vii) Passive/apathetic social withdrawal  
(viii) Lack of spontaneity and flow of conversation  
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Proposed items for remission criteria of psychopathology dimensions and DSM-IV and 
ICD-10 criteria for schizophrenia.
 
 (3) 
a  For symptomatic  remission, maintenance over a 6-month period of simultaneous 
ratings of mild or less on all items is required. Rating scale items are listed by item number.  
b  Use of BPRS criteria may be complemented by use of the SANS criteria for evaluating 
overall remission. 
 
 
Proposed remission criteria items 
Scale for 
Assessment of 
Positive Symptoms 
(SAPS) and Scale 
for Assessment of 
Negative 
Symptoms (SANS) 
items 
Positive and Negative 
Syndrome Scale items 
Brief Psychiatric 
Rating Scale 
(BPRS) items 
Dimension 
of 
psychopath
ogy 
DSM-IV 
criterion 
ICD-
10criterion 
 
Criterion 
 Item 
Criterion 
 
Item Criterion 
 
Item 
 
Psychoticis
m Delusions Delusions 
Delusions(SA
PS) 20 Delusions P1 Grandiosity 8 
(reality 
distortion
) 
Hallucinati
ons 
Hallucination
s 
Hallucination
s 
(SAPS) 
    7 Hallucinatory behavior P3 
Hallucinato
ry 
behavior 
12 
Disorganiza
tion 
Disorganiz
ed 
speech 
Breaks in train 
of thought, 
incoherence 
or 
irrelevant 
speech 
Positive 
formal 
thought 
disorder 
(SAPS) 
34 Conceptual disorganization P2 
Conceptual 
disorganiza
tion 
4 
Grossly 
disorganiz
ed 
or 
catatonic 
behavior 
Catatonic 
behavior 
Bizarre 
behavior 
(SAPS) 
25 Mannerisms/ posturing G5 
Mannerism
s/ 
posturing 
7 
Negative 
symptoms 
(psychom
otor 
poverty) 
Negative 
symptoms 
Negative 
symptoms 
Affective 
flattening 
(SANS) 
   7 Blunted affect N1 Blunted affect 16 
Avolition-
apathy 
(SANS) 
17 Social withdrawal N4 
No clearly 
related 
symptom 
 
Anhedonia-
Asociality 
(SANS) 
22     
Alogia 
(SANS) 13 
Lack of 
spontaneity N6 
No clearly 
related 
symptom 
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The symptom-based criterion can also be assessed using the 
SANS/SAPS (severity ≤2 points). The BPRS (severity ≤3 points) does 
not contain adequate representation of negative symptoms and is 
therefore alone not satisfactory for evaluating remission. The two 
negative symptoms not included in the BPRS (i.e., “social withdrawal” 
and “lack of spontaneity”) need to be additionally assessed with PANSS 
or SANS when BPRS is used. 
• A time criterion, which requires that an individual achieves the 
symptom-based criteria for a minimum of 6 months (2)
• Represent absolute severity of illness at any stage rather than relative 
improvement. 
. 
Advantages of RSWG criteria 
• Future studies using this criterion may allow for cross trial 
comparison(23)(24)(6)
• European working group welcomed this definition as it will improve 
clinical trial and decrease treatment expectation
. 
 (1)
• It can be applied for any patients who have been diagnosed with 
recognized criteria in the past. 
. 
• Remission criteria doesn`t invalidate the diagnosis. 
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• The criteria will not imply or depend on the causal mechanisms 
underlying the illness, or those that may have brought about 
remission(1)
Validity of the remission criteria 
. 
Since the publication of the remission criteria in March 2005, more 
than 50 articles on this topic have been published. Reviewing these 
articles brings about various problems: (i) many of the studies have used 
the symptom-severity remission criteria omitting the time criterion; (ii) 
some studies have used other outcome measures than the proposed 
PANSS, SANS/SAPS, or BPRS scales (e.g., CGI-S); (iii) some studies 
using the BPRS have not assessed the two missing negative symptoms of 
the severity criteria; (iv) There is a huge variation with respect to duration 
of study period; (v) some studies suffered from high dropout rates, if 
reported at all; (vi) finally, there is a huge variation regarding sample 
selection (e.g., acute inpatients vs. stable outpatients, first episode vs. 
multiple episode patients, schizophrenia vs. schizophrenia spectrum 
disorders, first-episode schizophrenia vs. first-episode psychosis 
including affective psychosis, patients with co morbid substance use 
disorder in or excluded, major differences in symptom severity at 
baseline, etc). Thus, comparability in terms of validity of criteria as well 
as frequencies and predictors of remission is limited (3). 
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For validation of remission criteria two different approaches were used:  
• Comparison of different definitions of symptomatic remission 
• Association of the remission criteria with various outcome dimensions 
including the overall symptomatic status, functional outcome, quality 
of life, or other outcome criteria. 
Comparison of different definitions of symptomatic remission: 
In 2005 and 2006, Sethuraman et al (25) and Dunayevich et al (26) 
compared the RSWG criteria with the criteria proposed by Lieberman et 
al (17).  The latter require that a patient achieve 50% reduction in BPRS 
total score, BPRS scores of ≤3 concurrently on each of the following 
BPRS psychosis items (unusual thought content, suspiciousness, 
hallucinations, conceptual disorganization, mannerisms, and posturing), 
and a Clinical Global Impressions-Severity (CGI-S) score ≤3 for a 
minimum of 8 weeks.  
The first post-hoc analysis by Sethuraman et al (25)
The second post-hoc analysis by Dunayevich et al
 concluded that 
the criteria by Lieberman et al are more stringent than the RSWG criteria.  
 (26) concluded 
that the Lieberman criteria appeared more stringent than the RSWG 
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criteria, as almost all patients achieving the Lieberman criteria also 
achieved the RSWG criteria, while the converse was not apparent. 
In 2006, van Os and colleagues (27) assessed whether a change in 
remission status would be associated with changes in clinician-reported 
and patient-reported functional outcomes. They concluded that change in 
remission status was associated with large differences in functional 
outcomes measured with the GAF and, to a lesser extent, in quality of 
life. This led the authors to conclude that the proposed remission criteria 
have “clinical validity.” 
In 2007, Leucht et al concluded that similar to the results by 
Sethuraman et al (25) and Dunayevich et al, (26) the Lieberman criteria were 
more stringent than the new RSWG criteria. The criteria proposed by 
Liberman et al (28) 
In 2008, Beitinger concluded that the results of more stringent 
thresholds within the proposed remission criteria (scores of ≤2 or lower) 
show that a score of mild or better is a “realistic choice, more stringent 
thresholds yield remission frequencies are not realistic.” 
were less restrictive. The authors concluded that a high 
stringency does not mean the most adequate remission criteria and that a 
major advantage of the new criteria is that they have been conceptualized 
and are based on the DSM-IV criteria for schizophrenia. 
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In 2009, Cassidy et al found that severity of both positive and 
negative symptoms is necessary although a 3 month criterion had equal 
predictive validity to a 6 month criterion. 
So compared to other remission criteria RSWG criteria has following 
advantages 
• The new remission criteria by Andreason et al (2) are less stringent than 
the remission criteria by Lieberman et al (17)
• The time criterion of 6 months was judged to be an appropriate cutoff 
because “shorter cutoff periods would be insufficient to permit 
validation of sustained and stable improvement.”
.  
(1)
• The rationale for selecting positive and negative symptom items for 
the remission definition seems reasonable because only definitions of 
remission containing both positive and negative symptoms were 
predictive of functional outcome, and both are core dimensions of 
schizophrenia. 
. 
• The non-consideration of the symptom items depression and 
suicidality seems reasonable because this inclusion did not change 
remission frequencies considerably. This supports the assumption of 
van Os et al, (1) who judged the exclusion of not diagnostically specific 
symptoms as appropriate because “they are influenced by other 
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factors, such as health care provision and cultural issues, which show 
great geographic and socioeconomic variability.” 
• Increasing the severity threshold to ≤2 (“very mild” or better) or 1 
(“not present”) means that hardly anybody will reach remission. This 
shows that a score of ≤3 `mild' or better is a realistic choice (29)
Association of symptomatic remission to outcome dimensions 
To date, 21 articles have published data on the relation of RWSG 
remission status to other outcome dimensions including the overall 
symptomatic status, functional outcome, quality of life, or other outcome 
dimensions. Three publications have assessed differences between 
already remitted and non remitted patients at baseline
. 
(30-32) and 14 
publications within a follow-up period of 6 months to 5 years(33-
45).Additionally, four publications have presented data on the percentage 
of patients in symptomatic remission fulfilling other outcome criteria(46-
49).  Following table (3) lists various studies measuring symptomatic status, 
functioning level and other outcome measures among symptomatic 
remission patients. Remission was defined as per RSWG criteria in these 
studies. 
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STUDY 
 N 
Assessment 
Baseline(BA) 
Follow up 
in/ months 
Remission 
Criteria 
Severity 
only(SC) 
Severity 
AND Time 
(STC) 
Remitted vs. Non remitted patients (NA=Not Assessed; NS=Not 
specified; mc=mean change; ns=not significant) 
Overall 
symptomatic or 
clinical status 
Functioning Quality of life 
Other outcome 
measures 
Helldin et 
al 211 BA SC NS NS NA BC,LCHC,LUN 
Ciudad et 
al 1010 BA SC NS SCOS:8vs11 
MCS-
12:37vs44 BSC 
Dunayevich 
et al 2771 6 SC 
PANSS mc -22 vs. -
11 NA 
QLS mc 
+15vs+4 NBC 
Buckley et 
al 184 6 SC NS NS NS NBC,LR 
Emsley et 
al 462 12 STC 
PANSS mc -41 vs. -
23 NA 
WQLS mc 
0.7 vs. 0.3  
Kelly et al 43 12 STC BPRS 28 vs. 34 NA 
QLS mc 
57 vs. 53 
ns 
 
Opler et al 675 12 STC PANSS 52 vs. 75 NA NA  
Lasser et al 578 12 STC PANSS 48 vs. 67 NA NS  
Kane et al 1283 12 STC CGI-I 1.7 vs. 3.7 NA NA  
De Hert et 
al 341 24 STC PECC 22 vs. 38 
GAF 64 vs. 
44 NA  
Wunderink 
et al 125 24 STC PANSS 44 vs. 52 
GSDS 5 vs. 
7 
WHOQOL 
98 vs. 97 
NS 
 
Emsley et 
al 57 24 STC PANSS 41 vs. 66 NA NA  
Addington 
et al 240 36 STC 
PANSS pos & neg 
19 vs. 35 NA 
QLS 85 
vs. 57  
Helldin et 
al 211 60 SC NS 49 vs. 66 NA NA LCHC 
Eberhard 
et al 115 60 STC NS 
GAF 68 vs. 
52 NA NBC 
Boden et al 76 60 SC NS 
Good 
function 
73% vs. 
17% 
NS  
 PANSS = Positive and Negative Syndrome Scale; BPRS = Brief Psychiatric Rating Scale; CGI-I = Clinical Global Impression-Improvement 
Scale; SCOS = Strauss-Carpenter Outcomes Scale; GAF = Global Assessment of Functioning Scale; GSDS = Groningen Social Disability 
Schedule; QLS = Quality of Life Scale; WQLS = Wisconsin Quality of Life Scale; MCS-12 = Mental Component Score of the Medical 
Outcomes Study 12-item Short Form health survey. (3) Other out- come dimensions: LCHC = Less consumption of health care; LR = 
Less relapse; BC = Better cognition; NBC = No better cognition; BDA = Better drug attitude; LUN = Less unmet needs; BSC = 
Better social cognition 
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Overall, patients in symptomatic remission were found to have a 
better symptomatic status, a better functioning level, and, to a lesser clear 
extent, a better quality of life and a better cognitive performance. 
Symptomatic status 
All longitudinal studies which reported data on the relation of 
RSWG remission to the overall symptomatic status (n=11) have found 
significantly better symptom status at follow-up or greater 
psychopathology mean change scores from baseline in remitted vs. non 
remitted patients. Using the PANSS total score, the difference between 
remitters and non remitters range between 8 points to 25 points at follow-
up with a mean difference of approximately 18 points and a mean change 
score difference of 17 points (-32 vs. -17). The average PANSS total 
score in remitters of 47 points underlines the low psychopathology level 
related to RSWG remission, but also suggests that the proposed criteria 
encompass symptomatic remission and not complete absence of 
symptoms.  
Important data with respect to the relation of remission to overall 
psychopathology were published by Opler et al (36).  Using the PANSS 
scale in a 1-year trial of assessing 675 patients, total score of 60 points at 
time points > 6 months (8 and 12 months), they found 85% patients who 
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had PANSS score above 60 were not in remission and 75% patients with 
score below 60 were in remission. 
Functional outcome 
The five studies, which assessed the relation between remission 
and functional outcome, all found a significantly better functioning level 
in remitted vs. non remitted patients.  
Study done by De Hert et al,2007 found that patients in remission 
had better insight in their disorder, a higher level of global functioning 
and functioned better with respect to daily living tasks, both compared to 
patients never meeting remission criteria and to patients only meeting the 
severity criterion but not the time criterion (39).  
A study done by Ciudad et al, 2007 found that symptomatic 
remission patients had significant greater Strauss Carpenter Social 
Functioning Score than unremitted patients. From 1010 patients analyzed, 
452 (44.8%) were at clinical remission, but only 103 (10.2%) showed an 
adequate social and/or vocational functioning (47). 
Study done by Wunderink et al, 2009 found that most functionally 
remitted patients were also symptomatically remitted, while a minority of 
symptomatically remitted patients were also functionally remitted (48).  
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Study done by Eberhard et al, 2009 found that symptomatic 
remission was strongly associated with global indices of illness, with 
intact insight and with social outcome (except work/studies) but not with 
cognition or medication. However he states that “word symptomatic 
remission could induce too much focus on symptom control” (44). 
Four studies (46)(47)(48)(49) assessed the proportion of patients in 
remission having a good functional level and found that only 30% to 38% 
of remitted patients at follow-up displayed an adequate functioning. For 
the interpretation of this result it is important to know that all three 
studies have set very stringent definitions of adequate functioning, i.e., 
GAF >80 points(46)(47) or adequate functioning in all 7 social roles in the 
GSDS scale(48) or fulfillment of vocational/occupation and independent 
living criteria for at least 6 months (49). On the other hand it is arguable 
whether the chosen severity level “mild or better” is really not associated 
with impaired functioning as proposed in the original description of the 
criteria. 
  (i) The fact of a significant difference in functioning between 
remitters and non remitters does not necessarily mean that remitters are 
functioning well. 
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(ii) That the stringency of the functioning criterion strongly 
influences the rates of patients who display an adequate functional 
outcome. 
(iii) That functioning in schizophrenia, in particular the 
vocational/occupational status is probably determined by others factors 
independent from remission status, e.g. common social and economic 
barriers of the general public in a given country. Besides, patients' 
functional outcome at follow-up is strongly influenced by the previous 
functioning level. For example, in a study by Catty et al, (50) assessing
With respect to quality of life, two studies by Kelly et al 
 
predictors of employment within an 18-month follow-up period in 312 
patients with psychotic disorders, previous work history, and RSWG 
remission where significant predictors of the number of hours employed 
(P=0.001 and P<0.001, respectively). 
Quality of life 
(35) and Emsley 
et al (34) have found no differences between remitted and non remitted 
patients.  While Ciudad et al (47), Dunayevich et al (26) and Addington et al 
(51) found a significantly better quality of life in remitted patients. 
However, studies assessing the frequency of remitted patients being in 
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adequate quality of life have found that only 60% to 70% of patients 
display a satisfying quality of life. 
With cognitive functioning 
Cognitive performance or neuropsychological improvements were 
not related to remission status in two of three studies (30)(26)(33). Further, 
the respective studies on cognition do not answer the question whether 
patients with remission display better cognitive functioning or if patients 
with a higher level of cognitive performance are more likely to meet 
remission criteria.  
Hofer et al studied the neurocognitive performance in symptomatic 
remitted patients and its influence on employment status through 
regression analysis in 2011, Austria. Remitted patients showed 
significantly higher values on tests of verbal fluency, alertness and optical 
vigilance. Both symptomatic remission as well as performance on tests of 
working memory and verbal memory had a significant effect on the 
patients' employment status. 
Sofia Brissos et al. Portugal 2011 found no significant different 
between remitted and unremitted group in cognitive function 
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Braw Y et al, Israel, 20012 studied the executive function in 
relation to symptom dimension severity from full remission to not 
remitted patients. A graded cognitive profile was evident between the 
groups. A significant role of negative symptoms in determining executive 
dysfunction in schizophrenia was also found. 
Symptomatic remission and real life functioning 
In 2012, a study was done to analyze the relationship between 
symptomatic remission and real life functioning. It was found that the 
symptomatic remission criteria has good ecological validity, patients who 
met the criteria reported fewer positive symptoms, better mood states and 
partial recovery of reward experience compared with those not in 
remission. However, remission status was not related to functional 
recovery, suggesting that the current focus on symptomatic remission 
may reflect an overly restricted goal (52). 
Most of the studies were done in developed countries whose 
outcome is different from developing countries like India. An Indian 
study compares the cognitive function of remitted patients with that of 
normal controls (53).  
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However studies measuring the relationship between symptomatic 
remission and outcome measures are lacking in India. Hence this study 
tries to measure the social functioning, quality of life and neurocognitive 
functioning of remitted patients and compare it with unremitted patients. 
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AIM  OF THE STUDY 
To study whether symptomatically remitted schizophrenia patients have 
better quality of life, social functioning and cognitive performance 
compared to unremitted patients.  
OBJECTIVES 
1. To assess quality of life, social functioning and cognitive 
performance in symptomatic remitted and unremitted 
schizophrenia patients. 
2. To compare quality of life, social functioning and cognitive 
performance in symptomatically remitted with unremitted 
schizophrenia patients. 
3. To find correlation between sociodemographic data, social function 
and cognitive functioning. 
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NULL HYPOTHESIS: 
1. No difference in quality of life between symptomatically 
remitted and unremitted patients. 
2. No difference in social functioning between symptomatically 
remitted and unremitted patients. 
3. No difference in cognitive function between symptomatically 
remitted and unremitted patients. 
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METHODOLOGY 
Study Centre: Institute of Mental Health, Madras Medical College, 
Chennai. 
Study type: Cross sectional observational study 
Study Sample: 30 patients in remitted group and 30 patients in 
unremitted group. 
Ethics Committee Approval: From Madras Medical College, Chennai 
Sample Selection: 
Schizophrenia patients who are attending the outpatient department for 
review are to be screened for the study. Consecutive 30 patients who 
fulfill remission criteria as defined by RSWG form one group. The 
other consecutive 30 patients who don`t fulfill remission criteria form 
second group.  
After explaining the complete nature of the study, consent to be 
obtained from both groups.  Patients who are consenting for research 
are to be taken. 
 
 
 
 36 
Selection criteria for remission group: 
Inclusion criteria  
1. Diagnosis of Schizophrenia according to DSM-IV TR. 
2. Subjects between 18 – 50 years of age. 
3. Formal primary education at least. 
4. Symptomatic remission -  Score :  ≤ 3(mild) in each following 
category of PANSS,   Delusions (P1), unusual thought content 
(A9), Hallucinatory behavior (P3) Conceptual Disorganization 
(P2), Mannerism /posturing (A5), Blunted Affect (N1),Social 
withdrawal (N4), Lack of spontaneity (N6) 
5. Stability of clinical symptoms in last 4 weeks 
6. Giving informed consent. 
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Exclusion criteria  
1. H/o any other psychiatric illness. 
2. H/o concurrent neurological illness or systemic illness known to 
impair cognition. 
3. Vision and hearing impaired. 
4. H/o head injury with loss of consciousness. 
5. H/o any substance dependence in preceding 6 months. 
Selection Criteria for Unremitted Group 
Those patients who score more than 3 in above said PANSS items for 
remission criteria but fulfilling other criteria for remitted group will be 
taken for study. 
Age less than 18 years was excluded to prevent inclusion of early 
onset of schizophrenia that was found to have more cognitive deficits and 
hence it could confound the results. Age more than 50 years was 
excluded to avoid age related cognitive decline affecting the results. 
Patients should have at least primary education to rule out intellectual 
disability and for easy assessment of cognitive function, as some tests 
cannot be done in illiterate patients. At the same time patients were 
enquired about their knowledge on English language as few tests involve 
English alphabets. 
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Tools to be employed: 
1. MINI PLUS – Structured diagnostic clinical interview for 
diagnosing Schizophrenia based on DSM IV TR criteria. 
2. A semi structured proforma for Socio demographic data and 
relevant clinical data. 
3. Clinical characteristics of patients including age of onset of illness, 
duration of untreated psychosis, total duration of illness, no of 
hospitalization in the past.  
4. Positive and Negative Symptom Scale (PANSS) to assess symptom 
severity. 
5. Personal and social performance scale (PSP) to assess social 
functioning. 
6. World Health Organization-Quality of Life BREF (WHOQOL-
BREF). 
7. Global Assessment of Functioning (GAF). 
8. Neuropsychological Assessment: 
Rey Auditory–Verbal Learning Test (RAVLT)-Verbal Learning 
and Memory. 
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Digit Symbol Coding – Attention, Concentration, Speed of 
processing. 
Trail making test (TMT) A and B – Motor speed and executive 
function. 
Verbal fluency - 1. Phonological 2. Semantic. 
Stroop Test – Selective attention, cognitive flexibility and 
processing speed, executive functions. 
Verbal N Back test (1 & 2) – Working Memory. 
MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW 
PLUS 
The M.I.N.I. was designed as a brief structured interview for the 
major Axis I psychiatric disorders in DSM-IV and ICD-10. Validation 
and reliability studies have been done comparing the M.I.N.I. to the 
SCID-P for DSM-III-R and the CIDI (a structured interview developed 
by the World Health Organization for lay interviewers for ICD-10).  The 
results of these studies show that the M.I.N.I. has acceptably high 
validation and reliability scores, but can be administered in a much 
shorter period of time (mean 18.7 ± 11.6 minutes, median 15 minutes) 
than the above referenced instruments.  It can be used by clinicians, after 
a brief training session.  Lay interviewers require more extensive training.   
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The M.I.N.I. Plus is a more detailed edition of the M.I.N.I. 
Symptoms better accounted for by an organic cause or by the use of 
alcohol or drugs should not be coded positive in the M.I.N.I.  The 
M.I.N.I. Plus has questions that investigate these issues (54). 
 
PANSS 
Positive and Negative Syndrome Scale is a rating scale to assess 
the psychopathology with gives scoring of positive symptoms, negative 
symptoms, general psychopathology, anergia, thought disturbance, 
activation, paranoid, depression (55)
The Personal and Social Performance scale
. 
 
PERSONAL AND SOCIAL PERFORMANCE SCALE (PSP) 
 (56) is a clinical tool 
assessing social functioning. The PSP assesses four functioning domains: 
1) socially useful activities, including work and study; 2) personal and 
social relationships; 3) self-care; and 4) disturbing and aggressive 
behaviors. These are rated on a six-point severity scale (absent to very 
severe), and based on these, the interviewer assigns a global score on a 
100-point scale (57). It also significantly correlated with Positive and 
Negative Syndrome Scale (PANSS), Global Assessment of Functioning 
(GAF) and Quality of Life Scale (QLS) at baseline (p<0.02) and with 
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CGI-S at follow-up (p<0.01). In addition, the PSP scale was moderately 
sensitive to the severity of illness (57). 
WHO-QOL BREF 
World Health Organization – Quality of Life Bref (WHO-QOL 
BREF) is an abbreviated version of WHO-QOL 100. The WHOQOL-100 
allows detailed assessment of each individual facet relating to quality of 
life.  In certain instances however, the WHOQOL-100 may be too 
lengthy for practical use.  The WHOQOL-BREF Version has therefore 
been developed to provide a short form quality of life assessment (58)
• Physical health Activities of daily living, Dependence on medicinal 
substances and medical aids, Energy and fatigue, Mobility, Pain 
and discomfort, Sleep and rest, Work Capacity 
. 
Quality of life is defined as individuals' perceptions of their 
position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and 
concerns.  
Four domains of quality of life are 
Physical Domain 
Psychological Domain 
• Psychological Bodily image and appearance, Negative feelings 
,Positive feelings, Self-esteem, Spirituality / Religion / Personal 
beliefs, Thinking, learning, memory and concentration 
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Social Domain 
• Social relationships, Personal relationships, Social support, Sexual 
activity 
Environmental Domain 
• Environment Financial resources, Freedom, physical safety and 
security, Health and social care: accessibility and quality, Home 
environment, Opportunities for acquiring new information and 
skills, Participation in and opportunities for recreation  / leisure 
activities, Physical environment (pollution / noise / traffic / 
climate), Transport. 
GLOBAL ASSESSMENT OF FUNCTIONING 
In psychiatry, the severity of illness can be scored by Global 
Assessment of Functioning (GAF). GAF is known worldwide and it is 
Axis V of the internationally accepted Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) It is 
constructed as an overall (global) measure of how patients are doing and 
rates psychological, social, and occupational functioning, covering the 
range from positive mental health to severe psychopathology. 
Internationally, GAF recorded values can be either a single score (only 
the most severe of the symptom and functioning values is recorded) or 
separate scores for symptoms (GAF-S) and functioning (GAF-F).  
For both the GAF-S and GAF-F scales, there are 100 scoring possibilities 
(1-100) (59). 
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COGNITIVE FUNCTIONING 
Categories used for assessment of cognition in schizophrenia were chosen 
from Brief Assessment of Cognition in Schizophrenia (BACS) (60). BACS 
is a neuropsychological assessment battery that specifically measures 
following six items 
1. Verbal Memory 
2. Working Memory 
3. Motor Speed 
4. Verbal Fluency 
5. Attention & Speed of information processing 
6. Executive function. 
These six items were found to be affected predominantly and were known 
to predict the outcome of schizophrenia. So the above categories were 
chosen for the study except motor speed. The corresponding tests for 
above categories were chosen from NIMHANS battery of 
neuropsychological Assessment. (61) They are 
Verbal Memory – Rey Auditory verbal learning test  
Working Memory - Verbal N Back test (1 & 2) 
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Verbal Fluency – Controlled oral word association test (COWAT) 
           Category Fluency (Animal Naming Test) 
Attention & Speed of information Processing – Digit Symbol Substitution 
Executive Function – Trail making Test part B; Trail making B/A ratio; 
Stroop test 
Motor Speed – Trail making test part A 
DIGIT SYMBOL SUBSTITUTION 
The digit symbol substitution test [Weschler, 1981]is test of visuomotor 
coordination ,motor persistence ,sustained attention and response speed. 
Rapid information processing is required in order to substitute the 
symbols accurately and quickly. The test consists of a sheet in which 
numbers 1-9 are randomly arranged in 4 rows of 25 squares each. The 
subject substitutes each number with a symbol using a number symbol 
key given on a top on a page. Time taken to complete the test forms the 
score. 
 
CONTROLLED ORAL WORD ASSOCIATION TEST 
The controlled Oral word Association test [Benton & Hamsher, 1989] is a 
measure of phonemic fluency. The subject generates words based on the 
phonetic similarity of words. The subject generates words beginning with 
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the letters F, A, S. Proper nouns and names of numbers should be 
excluded. The same word should not be repeated with a different suffix. 
In our adaptation, the subjects who do not know the English language are 
asked to generate words in their mother tongue, commencing with the 
consonants ‘KA’ PA’’.  MA’’ Score: The total number of acceptable new 
words produced in one minute is noted down for each trial. The average 
new words generated over 3 trials forms the score. 
 
CATEGORY FLUENCY:  
Category fluency is another form of fluency. In category fluency, unlike 
in phonemic fluency, it is the content of the words, rather than the 
phonetic similarity of the words, that is regulated. In a test, which 
measures category fluency, the subject generates words, which belong to 
a particular semantic category. The Animal names test [Lezak, 1995] 
requires the generate names of animals for the one minute. The total 
number of new words generated forms the score. 
 
REY’S AUDITORY VERBAL LEARNING TEST 
The Rey’s Auditory Verbal Leaning Test (AVLT) [Schmidt, 1996] 
adapted different cultures by WHO   [Maj  et  al,  1994] was adopted to 
suit conditions in India. Rey originally developed the test in 1964. It 
consists of words designating familiar objects like vehicles, tools, animals 
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and body parts. There are two lists A and B, with 15 different words in 
each list. The words were translated into the Indian language of Tamil. 
Words in List A are presented at rate of one word per second during 5 
successive trials. The words are presented in the same order in every trial. 
Each trial consists of the presentation of all 15 words, immediately 
followed by recall of the same. In each trial, after the presentation the 
subject is asked to recall the words but no cues are given. 30 minutes later 
recall of the words presented was scored. 
 
STROOP TEST 
Stroop test, named after John Ridley Stroop, measures the response 
inhibition.  In NIMHANS version, the color names “Blue, Green, Red 
and Yellow” are printed in capital letter on a paper. The color of the print 
occasionally corresponds with color designated by the word. The words 
are printed in 16 rows and 11 columns. Time taken read all the columns 
and name all the columns forms reading and naming scores respectively. 
The difference between naming and reading forms the effect score. 
 
TRAIL MAKING TEST 
Trail making test Part A & B [Lezak MD] measures cognitive 
dysfunction related to impairment in frontal lobe impairment. The test has 
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two parts: Part A involves a series of numbers and the participant is 
required to connect the numbers in sequential order (similar to a dot-to-
dot). Part B involves a series of numbers and letters and the participant is 
required to alternately connect letters and numbers in sequential order. 
The test generally requires ability to sequence (Parts A and B), ability to 
shift cognitive set (Part B), and processing speed (Parts A and B). Part A 
and Part B are scored separately and expressed in terms of the number of 
seconds it takes the participant to complete each section. 
 
For executive function, trail making part B was used for set shifting; 
Stroop test test for response inhibition. Trail making part B, B/A ratio and 
B-A (difference) were found to measure executive function (62). 
For motor speed, finger tapping test would be the ideal one. TMT pat A 
can be used as a proxy for measure of motor speed (63). So we have used 
TMT part A for motor speed. 
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STATISTICAL ANALYSIS 
 Comparison of  socio demographic data between two groups: Chi 
square test 
 Comparison of Clinical variables between two groups using t - test 
 Comparison of cognitive performance, social functioning and 
quality of life: t- test 
 Pearson Correlation between social functioning, sociodemographic 
data, clinical variables and cognitive functioning 
All statistical analysis was done using SPSS version 20 statistical 
software. Level of significance was kept at p<0.05. p<0.01 is 
highly significant. 
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RESULTS 
The present study compares two groups of schizophrenia patients. One 
group is comprised of schizophrenia patients under remission as defined 
by RSWG criteria. They will be called as ‘Remitted’ hereafter. The other 
group is schizophrenia patients not under remission who will be called as 
‘Unremitted’ hereafter. Each group consists of 30 patients and they are 
compared with appropriate statistics as mentioned then and there. 
SOCIODEMOGRAPHIC DATA 
 
Group 
Total 
P-Value Remitted Unremitted 
N % N % N % 
Sex 
Male 24 80.0 22 73.3 46 76.7 
0.542 
Female 6 20.0 8 26.7 14 23.3 
Education 
School 10 33.3 18 60.0 28 46.7 
0.040* 
College 20 66.7 12 40.0 32 53.3 
Occupation 
Unemployed 8 26.7 23 76.7 31 51.7 
<0.001** 
Employed 22 73.3 7 23.3 29 48.3 
Income/ Month 
No income 10 33.3 23 76.7 33 55.0 
0.001** 
Low income 3 10.0 1 3.3 4 6.7 
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Middle income 13 43.3 6 20.0 19 31.7 
High income 4 13.3 0 .0 4 6.7 
Marital Status 
Divorced 2 6.7 1 3.3 3 5.0 
0.384 
Married 14 46.7 15 50.0 29 48.3 
Unmarried 14 46.7 11 36.7 25 41.7 
Separated 0 .0 3 10.0 3 5.0 
Religion 
Hindu 28 93.3 25 83.3 53 88.3 
0.506 Christian 1 3.3 3 10.0 4 6.7 
Muslim 1 3.3 2 6.7 3 5.0 
Area 
Urban 22 73.3 20 66.7 42 70.0 
0.064 Semi Urban 8 26.7 5 16.7 13 21.7 
Rural 0 .0 5 16.7 5 8.3 
Total 30 100.0 30 100.0 60 100.0  
*p<0.05 significant **p<0.01 significant 
Among the single in marital status one man and two women are 
divorced; three women are separated from husband. There is significant 
difference between the groups in education, employment and income per 
month with remitted group having better education, employment and 
income per month. 
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ILLNESS DETAILS 
Illness Parameter Group N Mean 
Std. 
Deviation 
p value 
Age 
Remitted 30 34.00 6.314 
0.279 
Unremitted 30 36.10 8.430 
Onset of illness(Age) 
Remitted 30 25.97 4.979 
0.120 
Unremitted 30 24.03 4.499 
Duration of Untreated 
Psychosis 
Remitted 30 2.87 1.548 
0.015** 
Unremitted 30 4.00 1.930 
Total duration of 
illness 
Remitted 30 8.03 5.555 
0.023* 
Unremitted 30 12.07 7.634 
No of hospitalization 
in past 
Remitted 30 1.93 1.799 
0.862 
Unremitted 30 1.87 1.074 
PANSS Positive 
Remitted 30 7.80 3.809 
<.001** 
Unremitted 30 17.97 4.263 
PANSS Negative 
Remitted 30 11.47 3.589 
<.001** 
Unremitted 30 26.23 5.110 
PANSS General 
Psychopathology 
Remitted 30 19.83 5.663 
<.001** 
Unremitted 30 35.20 7.097 
PANSS Total Score 
Remitted 30 39.10 8.695 
.<.001** 
Unremitted 30 79.40 10.858 
*p<0.05 significant **
There is no significant difference between groups in age, age of 
onset of illness, no of hospitalization in the past. There is significant 
difference between groups in duration of untreated psychosis, total 
duration of illness, PANSS Positive, PANSS Negative, PANSS General 
Psychopathology and PANSS Total score. 
p<0.01 significant 
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QUALITY OF LIFE 
Domain Group N Mean Std. Deviation P-Values 
QOL physical 
Remitted 30 59.47 10.595 
0.003** 
Unremitted 30 51.83 8.579 
QOL psychological 
Remitted 30 62.03 11.874 
0.175 
Unremitted 30 57.77 12.204 
QOL social 
Remitted 30 60.97 10.115 
<0.001** 
Unremitted 30 44.73 15.373 
QOL environmental 
Remitted 30 63.80 8.475 
<0.001** 
Unremitted 30 42.67 12.609 
*p<0.05 significant **
 
p<0.01 significant 
The mean score of each domain for remitted group is higher than 
the unremitted group. There is significant difference between groups in 
physical, social and environmental domain. 
There is no significant difference between the groups in 
psychological domain. 
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PERSONAL AND SOCIAL PERFORMANCE 
Domain Group N Mean Std. Deviation P value 
PSP Self care 
Remitted 30 1.87 0.819 
<0.001** 
Unremitted 30 2.80 1.031 
PSP Social relationship 
Remitted 30 1.97 1.129 
<0.001** 
Unremitted 30 3.10 0.995 
PSP Useful activities 
Remitted 30 1.53 0.973 
<0.001** 
Unremitted 30 3.50 1.432 
PSP Aggression 
Remitted 30 1.40 0.621 
<0.001** 
Unremitted 30 2.57 1.331 
PSP Total Score 
Remitted 30 65.57 9.335 
<0.001** 
Unremitted 30 50.00 12.999 
*P<0.05 significant **
 
p<0.01 significant 
The mean score of each domain for remitted group is greater than 
the unremitted group. There is significant difference between the two 
groups in each domain. 
GLOBAL ASSESSMENT OF FUNCTIONING (GAF) 
Group N Mean 
Std. 
Deviation 
P value 
GAF 
Remitted 30 63.03 8.779 <0.001** 
Unremitted 30 48.73 11.176 <0.001** 
*p<0.05 significant **
 
p<0.01 significant 
The mean GAF score of remitted group is greater than the 
unremitted group. There is significant difference between the groups in 
the GAF score. 
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PERCENTAGE OF PATIENTS WITH  
ADEQUATE FUNCTIONING 
 
 
GAF PSP 
Group 0-60 61-100 0-70 71-100 
Remitted (n %) 53.33 46.66 80 20 
Unremitted (n %) 83.33 16.66 100 0 
 
GAF score of 61 and above was found to have mild symptoms or 
no symptoms/difficulties. GAF score above 80 was considered as 
adequate functioning (46). Since none of our sample reached GAF score of 
80, a cut off of 60 was chosen for comparison of adequacy of functioning. 
In remitted group, 46.66% was found to have adequate functioning 
with mild symptoms and only 16.66% was found to have adequate 
functioning with mild symptoms. 
PSP score of 71 and above is found to have mild or no difficulty in 
social functioning (64). Only 20 percent of remission group was found to 
have adequate social functioning and none in unremitted group. 
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COGNITIVE FUNCTIONING 
Attention and speed of processing 
DIGIT SYMBOL SUBSTITUTION 
  Group N 
Mean 
(Sec) 
Std. Deviation P value 
Digit Symbol Substitution 
Remitted 30 241.33 39.031 <0.001** 
Unremitted 30 307.33 81.074 <0.001** 
*p<0.05 significant **
  
p<0.01 significant 
The mean duration for digit symbol substitution in remitted group 
is 241.33 second and in unremitted group is 307.33 second. There is 
significant difference between their scores. 
Motor Speed 
TRAIL MAKING TEST A (TMT A) 
Group N 
Mean 
(sec) 
Std. Deviation P value 
TMT A 
Remitted 30 63.03 17.661 0.003** 
Unremitted 30 78.50 20.263 0.003** 
*p<0.05 significant **
The mean duration for completion of trail making test part A is 
63.03 second and 78.50 second in remitted and unremitted group 
respectively. There is significant difference between the groups in the 
mean scores.  
p<0.01 significant 
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Verbal learning and Memory 
REY AUDITORY VERBAL LEARNING TEST (RAVLT) 
Trials Group N Mean Std. Deviation P value (ns) 
Trial 1 
Remitted 30 7.03 1.217 
0.092 
Unremitted 30 6.50 1.196 
Trail 2 
Remitted 30 7.47 1.224 
0.117 
Unremitted 30 7.03 .850 
Trial 3 
Remitted 30 7.60 1.404 
0.434 
Unremitted 30 7.33 1.213 
Trial 4 
Remitted 30 7.87 1.592 
0.280 
Unremitted 30 7.47 1.224 
Trial 5 
Remitted 30 8.77 1.569 
0.228 
Unremitted 30 8.30 1.393 
Verbal Learning 
Remitted 30 38.73 6.119 
0.142 
Unremitted 30 36.63 4.723 
Immediate Recall 
Remitted 30 7.00 1.259 
0.437 
Unremitted 30 6.77 1.040 
Delayed Recall 
Remitted 30 6.10 1.348 
0.476 
Unremitted 30 5.87 1.167 
LTPR 
Remitted 30 69.78 9.810 
0.778 
Unremitted 30 70.53 10.62 
Recognition Hits 
Remitted 30 9.03 2.205 
0.827 
Unremitted 30 8.93 1.172 
Recognition Errors 
Remitted 30 9.00 2.913 
0.504 
Unremitted 30 9.43 1.995 
LTPR – Long term percent retention   *
 
p<0.05 significant         ns-not significant 
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The first five trials and Total of the five trials measures verbal 
learning. The mean score of each trial for remitted group is higher than 
the unremitted group. There is no significant difference between the 
groups in each trial and total score. 
The immediate recall, delayed recall and LTPR are measures of 
memory. The mean score of these variables is higher in remitted group 
compared to unremitted group. But there is no significant difference 
between the groups. 
Working memory 
VERBAL N-BACK TEST 
  Group N Mean Std. Deviation P value 
N-Back 1 Score 
Remitted 30 8.73 .868 0.036* 
 Unremitted 30 9.27 1.048 
N-Back 2 Score 
Remitted 30 8.90 .662 0.007** 
 Unremitted 30 8.23 1.135 
*p<0.05 significant **
 
p<0.01 significant 
The mean score of verbal n-back tests 1 and 2 for remitted group is 
higher than the unremitted group. There is statistically significant 
difference between their mean scores for N – Back 1 Score. There is very 
high significant difference between the groups in N – Back 2 Score. 
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Verbal Fluency 
COWAT (CONTROLLED ORAL WORD ASSOCIATION TEST) 
 
Group N Mean Std. Deviation P value 
COWAT 
Remitted 30 7.20 2.058 <0.001** 
Unremitted 30 4.33 0.959 <0.001** 
*p<0.05 significant **
 
p<0.01 significant 
COWAT test measures phonological fluency. The mean score of 
remitted group is greater than the unremitted group. There is significant 
difference between the groups. 
 
ANIMAL NAMING TEST 
Group N Mean Std. Deviation P value 
Animal Naming Test 
Remitted 30 8.03 2.539 <0.001** 
Unremitted 30 5.27 1.311 <0.001** 
*p<0.05 significant **p<0.01 significant 
Animal naming test measures the categorical fluency or semantic 
fluency. The mean score of remitted group is greater than the unremitted 
group. There is significant difference between the groups in their scores.  
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Executive Functioning 
TRAIL MAKING PART B (TMT B) 
 
Group N Mean(sec) Std. Deviation P value 
TMT-Part B 
Remitted 30 145.00 48.831 
<0.001** 
Unremitted 30 198.33 55.029 
TMT B-A 
Remitted 30 81.97 43.042 
0.001** 
Unremitted 30 119.83 38.585 
TMT B/A 
Remitted 30 2.3770 .74479 
0.281 
Unremitted 30 2.5410 .35412 
*p<0.05 significant **p<0.01 significant 
In trail making test Part B, the mean score of remitted group is 
lesser than the unremitted group. There is high significant difference 
between the groups also. 
Trail making test B – A: The score is calculated by subtracting 
TMT part B score from part A. This eliminates motor speed as 
confounding variable. The mean score for remitted score is lesser than the 
unremitted group and there is significant difference between the groups. 
Trail making test B/A: The score is calculated by division of Part B 
score with Part A score. The mean score of remitted score is lesser than 
the unremitted group. There is no significant difference between the 
groups. 
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STROOP TEST 
 
Group N Mean Std. Deviation P value (ns) 
Stroop-Reading 
Remitted 30 122.80 22.188 
0.935 
Unremitted 30 123.23 18.532 
Stroop-Naming 
Remitted 30 371.80 75.983 
0.967 
Unremitted 30 372.60 74.456 
Stroop-Effect Score 
Remitted 30 249.00 59.989 
0.982 
Unremitted 30 249.37 65.855 
ns-not significant 
The mean score for remitted group is lesser than the unremitted 
group. There is no significant difference between the groups. The mean 
scores are almost equal. 
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Correlation between Sociodemographic and Psychopathology data 
  PANSS Positive  PANSS Negative   
PANSS General 
Psychopathology   
Age 0.072 0.135 0.138 
Sex 0.095 -0.027 0.078 
Education -0.234 -0.309 -0.314* * 
Employment -0.556 -0.571** -0.600** ** 
Income per month -0.472 -0.508** -0.612** ** 
Marital status -0.126 -0.017 0.148 
Religion 0.096 0.197 0.349** 
Background 0.108 -0.039 0.050 
Pearson Correlation [r] 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
There is significant correlation between the dimensions of all 
PANSS psychopathology and employment & income per month. There is 
significant correlation between PANSS Negative & General 
Psychopathology and Education.   
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Correlation between Illness factors and Psychopathology 
  PANSS Positive  PANSS Negative   
PANSS General 
Psychopathology   
Onset of illness(Age) -0.285 -0.231 * -0.165 
Duration of Untreated Psychosis 0.327 0.250 * 0.320* 
Total duration of illness 0.275 0.305* 0.263* * 
No of hospitalization in past 0.149 0.026 0.094 
Pearson Correlation [r] 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
There is significant positive correlation PANSS positive with 
duration of untreated psychosis and total duration of illness. There is 
significant negative correlation PANSS positive with age of onset of 
illness.  
There is significant positive correlation of PANSS negative with 
total duration of illness.  
There is significant positive correlation between PANSS general 
psychopathology and duration of untreated psychosis & total duration of 
illness.  
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Correlation between Cognitive function and Psychopathology 
  PANSS Positive  PANSS Negative   PANSS General Psychopathology  
TMT-A 0.323 0.296* 0.334* ** 
TMT-B 0.405 0.465** 0.481** ** 
TMT B-A 0.379 0.469** 0.472** ** 
TMT B/A 0.148 0.272 0.238 * 
Stroop-Effect Score -0.003 0.029 -0.041 
N-Back 1 Score 0.053 0.325 0.094 * 
N-Back 2 Score -0.287 -0.212 * -0.406** 
Animal naming test -0.440 -0.474** -0.297** * 
COWAT -0.522 -0.604** -0.567** ** 
Digit Symbol 
Substitution 0.326 0.376
* 0.363** ** 
Verbal Learning -0.246 -0.095 -0.156 
Immediate Recall  0.003 0.025 -0.086 
Delayed Recall -0.038 0.009 -0.118 
LTPR 0.184 0.067 -0.028 
Pearson Correlation [r] 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
TMT A & B, TMT B - A, Digit symbol substitution has significant 
positive correlation with all domains of PANSS psychopathology. Verbal 
semantic (Animal naming test) and Phonological fluency have significant 
negative correlation with all domains of PANSS psychopathology. TMT 
B/A have significant positive correlation with PANSS negative domain. 
No signification correlation of PANSS with Stroop test, verbal learning 
and memory.  
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Correlation between Sociodemographic data and Quality of life 
  
WHO-QOL 
Physical  
WHO-QOL 
Psychological  
WHO-QOL 
 Social  
WHO-QOL 
Environmental  
Age -0.030 0.006 -0.123 -0.072 
Sex -0.178 -0.087 0.047 -0.077 
Education 0.207 0.081 0.165 0.249 
Employment 0.637 0.588** 0.635** 0.603** ** 
Income per month 0.652 0.523** 0.577** 0.555** ** 
Marital status -0.095 -0.088 -0.040 -0.119 
Religion -0.132 -0.142 -0.109 -0.151 
Background -0.091 -0.061 -0.178 -0.171 
Pearson correlation [r] 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Employment and income per month have significant positive 
correlation with the quality of life. Other variables have no significant 
correlation with quality of life.  
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Correlation between Illness parameters and Quality of Life 
 
WHO-QOL 
Physical  
WHO-QOL 
Psychological  
WHO-QOL 
Social  
WHO-QOL 
Environmental  
Onset of illness(Age) 0.185 0.116 0.175 0.179 
Duration of Untreated 
Psychosis 
-0.185 -0.234 -0.258 -0.248 * 
Total duration of illness -0.161 -0.074 -0.254 -0.201 
No of hospitalization in past -0.233 -0.435 -0.134 ** -0.116 
PANSS Positive -0.453 -0.356** -0.562** -0.655** ** 
PANSS Negative -0.529 -0.290** -0.577* -0.687** ** 
PANSS General 
Psychopathology 
-0.463 -0.350** -0.612** -0.678** ** 
PANSS Total Score -0.540 -0.370** -0.656** -0.754** ** 
Pearson correlation [r] 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
There is significant negative correlation of quality of life with all 
domains of PANSS. There is significant negative correlation between 
WHO-QOL social and duration of untreated psychosis. There is 
significant negative correlation between WHO-QOL psychological and 
no of hospitalization.  
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Correlation between Cognitive function and Quality of Life 
  
WHO-QOL 
Physical  
WHO-QOL 
Psychological  
WHO-QOL  
Social  
WHO-QOL 
Environmental  
TMT-A -0.152 -0.138 -0.277 -0.332* ** 
TMT-B -0.365 -0.221 ** -0.396 -0.442** ** 
TMT B-A -0.405 -0.224 ** -0.388 -0.422** ** 
TMT B/A -0.319 -0.139 * -0.204 -0.184 
Stroop-Effect Score -0.149 -0.007 0.102 0.013 
N-Back 1 Score -0.056 0.168 -0.062 -0.216 
N-Back 2 Score 0.084 0.055 0.235 0.282* 
Animal naming test 0.052 -0.078 0.193 0.329* 
COWAT 0.245 0.054 0.325 0.441* ** 
Digit Symbol Substitution -0.279 -0.059 * -0.122 -0.221 
Verbal Learning -0.084 -0.092 0.068 0.212 
Immediate Recall  -0.292 -0.261* -0.072 * 0.019 
Delayed Recall -0.175 -0.182 0.031 0.079 
LTPR -0.135 -0.173 -0.024 -0.158 
Pearson correlation [r] 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
WHOQOL Physical has significant negative correlation with TMT 
B, TMT B-A, TMT B/A, digit symbol substitution and immediate recall 
in RAVLT. WHOQOL Psychological has significant negative correlation 
with immediate recall in RAVLT. WHOQOL Social has negative 
correlation with TMT A, TMT B, TMT B-A and positive correlation with 
verbal phonological (COWAT) fluency. WHOQOL Environment has 
significant negative correlation with TMT A, TMT B, TMT B/A and 
positive correlation with N-Back 2 score and phonological verbal fluency. 
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Correlation between Sociodemographic data and Social Functioning 
  GAF PSP Total Score 
Age -0.207 -0.113 
Sex -0.253 -0.165 
Education 0.358 0.352** ** 
Employment 0.816 0.797** ** 
Income per month 0.793 0.777** ** 
Marital status -0.195 -0.236 
Religion -0.176 -0.216 
Background -0.247 -0.271* 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Personal and Social Performance (PSP) score has significant 
positive correlation with education, employment, income per month. It 
has significant negative correlation with background. GAF has significant 
positive correlation with education, employment and income per month 
as for PSP. 
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Correlation between Illness factors and Social Functioning 
 
GAF PSP Total Score 
Onset of illness(Age) 0.269 0.281* * 
Duration of Untreated Psychosis -0.438 -0.456** ** 
Total duration of illness -0.409 -0.317** * 
No of hospitalization in past -0.220 -0.160 
PANSS Positive -0.613 -0.592** ** 
PANSS Negative -0.658 -0.598** ** 
PANSS General Psychopathology -0.639 -0.653** ** 
PANSS Total Score -0.714 -0.691** ** 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Personal and Social Performance and GAF have significant 
positive correlation with age of onset of illness and significant negative 
correlation with duration of untreated psychosis, total duration of illness 
and all domains of PANSS score.  
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Correlation between Cognitive Function and Social Functioning 
 
GAF PSP Total Score 
TMT-A -0.351 -0.347** ** 
TMT-B -0.508 -0.489** ** 
TMT B-A -0.500 -0.478** ** 
TMT B/A -0.278 -0.240 * 
Stroop-Effect Score 0.022 0.011 
N-Back 1 Score -0.154 -0.081 
N-Back 2 Score 0.081 0.125 
Animal naming test 0.312 0.259* * 
COWAT 0.422 0.433** ** 
Digit Symbol Substitution -0.296 -0.322* * 
Verbal Learning -0.023 -0.046 
Immediate Recall  -0.250 -0.233 
Delayed Recall -0.241 -0.225 
LTPR -0.202 -0.179 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Personal and Social Performance and GAF has significant negative 
correlation with TMT A, TMT B, TMT B-A and digit symbol 
substitution. PSP and GAF have significant positive correlation with 
verbal phonological (COWAT) and semantic fluency scores. GAF has 
significant negative correlation with TMT B/A. 
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DISCUSSION 
AGE 
The mean age of patients in remitted group was 34 years and 
unremitted group was 35 years. This is because of the sample selection 
criteria which specify age group between 18 years and 50 years. A similar 
study done in India in outpatient setting has similar age group of 
schizophrenia patients (65)
 
. There is no significant difference between the 
groups in age. Age is not found to correlate with psychopathology, 
quality of life and social functioning in this study. 
SEX 
Sample consists mostly of males; 80% in remitted group and 73% 
in unremitted group. This may be because of study setting which is done 
in outpatient department. A future study measuring frequency distribution 
of sex of the patients attending outpatient department may find a reason. 
Moreover few female patients refused to participate in study because of 
time constraint and few were excluded as they had no formal education. 
No sex difference observed in our study and was found not to correlate 
with any outcome measures. 
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EDUCATION 
Patients in remitted group were better educated than the unremitted 
group in our sample. There was significant difference between the groups 
with more remitted population having attended college.  
EMPLOYMENT, INCOME PER MONTH 
Remitted group had a significant population being employed and 
good income per month in terms of income per month. Employment is 
correlated with positive outcomes in social functioning, symptom level, 
quality of life and self esteem (66). 
AGE OF ONSET OF ILLNESS 
The mean age of onset of illness is 26 years in remitted group and 
24 years in unremitted group. The peak age of onset of illness is from 10 
to 25 years (67)
The mean Duration of untreated psychosis in our sample is 36 
months and 48 months in remitted and unremitted group respectively. 
. Since the study included population between 18-50 years, 
our study comprised of relatively late onset. Our study findings showed 
that earlier age of onset is associated with greater psychopathology and 
poor outcome.  
DURATION OF UNTREATED PSYCHOSIS 
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Though the mean duration of untreated psychosis is 6 months to 2 years, 
studies reporting DUP as long as 10 years have been reported which is 
primarily because of lack of availability and accessibility of mental health 
services rather than the psychosis remaining 'unidentified' (68)(69). In our 
study, it was found that longer the duration of untreated psychosis; 
greater the PANSS positive and general psychopathology scores. Similar 
to other studies (70), duration of untreated psychosis was found to strong 
negative correlation with outcome scores. 
TOTAL DURATION OF ILLNESS 
The mean total duration of illness is 8 years and 12 years for 
remitted and unremitted group respectively. Total duration of illness also 
had positive correlation with symptom severity and negative correlation 
with outcome of schizophrenia as in previous research (71). 
NO OF HOSPITALIZATION IN THE PAST 
Hospitalization is a good proxy outcome measure in schizophrenia 
(72)
 
. However there is no significant difference the groups in our study. 
Hospitalization was also not found to correlate with outcome and quality 
of life in our study. 
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PANSS 
Since we are dividing schizophrenia patients into two groups based 
on PANSS, it was expected to have significant difference. Remitted 
group`s total mean score was 40.  The mean score of total PANSS in 
unremitted group is 80. Better symptomatic status as reported by many 
studies (30-40) is replicated here. 
QUALITY OF LIFE 
In our study, there was significant difference between the groups in 
physical, psychological and environmental domain WHOQOL score. 
This is consistent with similar studies done recently(1)(73)(45)(32)(26)(34)(37) and 
contrary to some studies which found weak or no correlation between 
symptom severity and quality of life as such(74-76)
The subjective quality of life was also better when the patient 
employed and having better income per month.  In our study duration of 
untreated psychosis has negative correlation with WHO QOL social 
domain. This is consistent with studies reporting better social functioning 
with less duration of untreated psychosis
.  
 
 (70). The relationship between 
quality of life and neurocognitive functioning is complex. Few domains 
have significant relationship with cognitive functioning. Verbal fluency 
and motor speed have significant positive correlation with quality of life. 
 74 
Memory and executive functions have no significant relationship. These 
findings are contrary to previous studies (77)(78). 
 
SOCIAL FUNCTIONING 
The social functioning of remitted group was better than the 
unremitted group as measured by Global Assessment of Functioning and 
Personal and Social Performance score. This is consistent with many 
recent studies (32)(39)(79)(44)(76)
 
. Remitted group was also significantly better 
in all four domains of personal and social performance scale. 
Severity of symptom also had negative impact on social 
functioning along with other sociodemographic and illness factors like 
education, employment, duration of untreated psychosis, age of onset and 
total duration of illness.  
 
However in remission group only 20% had adequate social 
functioning when measured by PSP score. None of the patient achieved 
adequate functioning when GAF score of 80 was set as cut off. Though 
there are significant differences between the groups in GAF and PSP 
score, symptom remission alone is not adequate for social functioning.  
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COGNITIVE FUNCTIONING 
Remitted group was better than the unremitted group in attention, 
speed of processing, motor speed, working memory, verbal fluency. 
There is no significant difference between the groups in verbal learning 
and executive functions, in part.  
Cognitive function of symptomatically remitted patients is better 
than unremitted group. Similar finding has been observed in recent study 
also (31). But the results are contrary to other studies as well (34)(44)
 
. 
Symptom dimensions also had significant correlation with 
correlation in attention, speed of processing, motor speed, verbal fluency, 
working memory. Negative syndrome dimension had significant 
correlation with executive function, as measured by TMT B/A. This is 
similar to previous research by Braw et al and Hofer et al. 
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CONCLUSION 
• Symptomatic remission group is found to have better quality of life 
and outcome in terms of personal and social performance. 
• Symptomatic remission group is found to have better cognition in 
attention, speed of processing, motor speed, working memory and 
verbal fluency. 
• Education and duration of untreated psychosis were found to have 
consistent correlation with symptom status and outcome measures. 
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LIMITATIONS 
• Study was conducted in tertiary care centre which may not be 
representative of general population.  
• Study sample was selected from review OPD. Patients who are 
coming to review OPD are either more functional or more 
symptomatic. Hence it may not represent the cases in between these 
two extremes. Results cannot be generalized for schizophrenia 
population. 
• Study would have been better if normal control group is included for 
comparison of cognitive functioning. 
• Addition of a normal control group would have allowed better 
understanding of real life functioning of remitted group if they were 
compared. 
• Statistical analysis for cognitive assessment would have been better if 
analyzed using ANCOVA with education as a co variant because there 
is statistical significant difference between groups. 
• Effect of medication on cognitive function was not taken into account. 
• Study would have been better if more factors like family history, drug 
compliance, drug attitude, pre morbid functioning, expressed emotions 
etc were analyzed as it may throw some light over predictors of 
remission. 
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RECOMMENDATIONS 
Symptomatic remission is associated with better quality of life, social 
functioning and cognitive function, to some extent. 
Hence achieving symptomatic remission should be kept as one goal for 
attaining recovery. 
Future studies should analyze the following issues: 
1.  Predictors of symptomatic remission. 
2.  Assessment of symptomatic remission using RSWG criteria is a 
good indicator of functional recovery. So future studies using this 
criteria may allow cross comparison. 
3.  Drug trials should be aimed at achieving symptomatic remission 
rather than just response. 
4.  Non pharmacological interventions in achieving symptomatic 
remission and maintaining symptomatic remission should be 
studied. 
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PATIENT DETAILS
Patient ID Age - Sex - M/F Date Time
Education - Illiterate / school educated / college educated
Occupation - Working / Not working
Income - / Month
Marital status - Married / Unmarried / Separated / Divorced
Religion - Hinduism / Islam / Christianity / Others
Background - Rural / Urban
Onset of Illness (Age) -
Duration of Untreated Psychosis -
No of Hospitalization in past -
PANSS- [P]…… [N]……..[G]…….[T]…..
WHO QOL Bref: Physical…. Psy….. Social…. Environmental……
GAF –
PSP Score – Self care…… Relationship…. ..Useful Activity…….. Aggression……
TMT-A
TMT-B
STROOP TEST: READING NAMING EFFECT SCORE
VERBAL N BACK TEST: 1 Back Score…….. 2 Back Score…….
DIGIT SYMBOL SUBSTITUITION –
VERBAL FLUENCY Phonological = Semantic =
VERBAL LEARNING TEST

















 
